

# Rimas J Orentas

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11142584/publications.pdf>

Version: 2024-02-01

27  
papers

5,057  
citations

430874

18  
h-index

610901

24  
g-index

27  
all docs

27  
docs citations

27  
times ranked

6365  
citing authors

#	ARTICLE	IF	CITATIONS
1	4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors. <i>Nature Medicine</i> , 2015, 21, 581-590.	30.7	1,304
2	CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy. <i>Nature Medicine</i> , 2018, 24, 20-28.	30.7	1,030
3	Anti-CD22 chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia. <i>Blood</i> , 2013, 121, 1165-1174.	1.4	478
4	CAR T Cells Targeting B7-H3, a Pan-Cancer Antigen, Demonstrate Potent Preclinical Activity Against Pediatric Solid Tumors and Brain Tumors. <i>Clinical Cancer Research</i> , 2019, 25, 2560-2574.	7.0	369
5	Tumor Antigen and Receptor Densities Regulate Efficacy of a Chimeric Antigen Receptor Targeting Anaplastic Lymphoma Kinase. <i>Molecular Therapy</i> , 2017, 25, 2189-2201.	8.2	264
6	Reduction of MDSCs with All-trans Retinoic Acid Improves CAR Therapy Efficacy for Sarcomas. <i>Cancer Immunology Research</i> , 2016, 4, 869-880.	3.4	258
7	CD19 CAR T cell product and disease attributes predict leukemia remission durability. <i>Journal of Clinical Investigation</i> , 2019, 129, 2123-2132.	8.2	244
8	A tandem CD19/CD20 CAR lentiviral vector drives on-target and off-target antigen modulation in leukemia cell lines. , 2017, 5, 42.		196
9	Fibrocytes represent a novel MDSC subset circulating in patients with metastatic cancer. <i>Blood</i> , 2013, 122, 1105-1113.	1.4	144
10	Locoregional infusion of HER2-specific CAR T cells in children and young adults with recurrent or refractory CNS tumors: an interim analysis. <i>Nature Medicine</i> , 2021, 27, 1544-1552.	30.7	138
11	Eradication of B-ALL using chimeric antigen receptor-expressing T cells targeting the TSLPR oncoprotein. <i>Blood</i> , 2015, 126, 629-639.	1.4	110
12	Persistent Polyfunctional Chimeric Antigen Receptor T Cells That Target Glypican 3 Eliminate Orthotopic Hepatocellular Carcinomas in Mice. <i>Gastroenterology</i> , 2020, 158, 2250-2265.e20.	1.3	97
13	Retroviral Transduction of a T Cell Receptor Specific for an Epstein-Barr Virus-Encoded Peptide. <i>Clinical Immunology</i> , 2001, 98, 220-228.	3.2	87
14	Identification of Cell Surface Proteins as Potential Immunotherapy Targets in 12 Pediatric Cancers. <i>Frontiers in Oncology</i> , 2012, 2, 194.	2.8	81
15	Trispecific CD19-CD20-CD22-targeting duoCAR-T cells eliminate antigen-heterogeneous B cell tumors in preclinical models. <i>Science Translational Medicine</i> , 2021, 13, .	12.4	77
16	A Unique Human Immunoglobulin Heavy Chain Variable Domain-Only CD33 CAR for the Treatment of Acute Myeloid Leukemia. <i>Frontiers in Oncology</i> , 2018, 8, 539.	2.8	32
17	Feasibility of Cellular Adoptive Immunotherapy for Epstein-Barr Virus-Associated Lymphomas Using Haploidentical Donors. <i>Stem Cells and Development</i> , 1998, 7, 257-261.	1.0	31
18	Transduction of Primary Lymphocytes with Epstein-Barr Virus (EBV) Latent Membrane Protein-Specific T-Cell Receptor Induces Lysis of Virus-Infected Cells: A Novel Strategy for the Treatment of Hodgkin's Disease and Nasopharyngeal Carcinoma. <i>Journal of Clinical Immunology</i> , 2006, 26, 22-32.	3.8	27

#	ARTICLE	IF	CITATIONS
19	Lessons learned from a highly-active CD22-specific chimeric antigen receptor. <i>Oncolimmunology</i> , 2013, 2, e23621.	4.6	25
20	Self-driving armored CAR-T cells overcome a suppressive milieu and eradicate CD19+ Raji lymphoma in preclinical models. <i>Molecular Therapy</i> , 2021, 29, 2691-2706.	8.2	18
21	Paired Expression Analysis of Tumor Cell Surface Antigens. <i>Frontiers in Oncology</i> , 2017, 7, 173.	2.8	16
22	Bioinformatic Description of Immunotherapy Targets for Pediatric T-Cell Leukemia and the Impact of Normal Gene Sets Used for Comparison. <i>Frontiers in Oncology</i> , 2014, 4, 134.	2.8	13
23	CAR-T Therapy for Lymphoma with Prophylactic Tocilizumab: Decreased Rates of Severe Cytokine Release Syndrome without Excessive Neurologic Toxicity. <i>Blood</i> , 2020, 136, 30-31.	1.4	6
24	Bryostatin Activates CAR T-Cell Antigen-Non-Specific Killing (CTAK), and CAR-T NK-Like Killing for Pre-B ALL, While Blocking Cytolysis of a Burkitt Lymphoma Cell Line. <i>Frontiers in Immunology</i> , 2022, 13, 825364.	4.8	6
25	Combining Immunocytokine and Ex Vivo Activated NK Cells as a Platform for Enhancing Graft-Versus-Tumor Effects Against GD2+ Murine Neuroblastoma. <i>Frontiers in Immunology</i> , 2021, 12, 668307.	4.8	4
26	Promising Chimeric Antigen Receptors for Non-B-Cell Hematological Malignancies, Pediatric Solid Tumors, and Carcinomas. , 2020, , 137-163.		2
27	T-Cell Immunotherapy: From Synthetic Biology to Clinical Practice. , 2021, , 199-218.		0